Results 1 to 10 of about 43,829 (141)

Infliximab

Reactions Weekly, 2006
europepmc   +5 more sources

Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn’s disease: a retrospective cohort study

BMC Gastroenterology, 2022
Background Recent studies have confirmed that combined surgery and anti-TNF therapy could improve outcomes in patients with perianal fistulising Crohn’s disease (PFCD).
Ping Zhu, Jin-fang Sun, Yun-fei Gu, Hong-jin Chen, Min-min Xu, You-ran Li, Bo-lin Yang   +6 more
doaj   +1 more source

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab

Gut and Liver, 2023
Background/Aims: The clinical efficacy and safety of CT-P13 are comparable to originator infliximab for Crohn’s disease in CT-P13 3.4 study (NCT02096861).
Jihye Park, Jae Hee Cheon, Kang-Moon Lee, Young-Ho Kim, Byong Duk Ye, Chang Soo Eun, Sung Hyun Kim, Sun Hee Lee, Joon Ho Lee, Stefan Schreiber   +9 more
doaj   +1 more source

Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease. [PDF]

PLoS ONE, 2018
Overt fibrostenotic disease is a relative contraindication for anti-TNF therapy in Crohn's disease. We hypothesized that subclinical fibrosis may also contribute to an incomplete response to anti-TNF therapy before the onset of symptomatic stenosis.In a ...
Jessica R de Bruyn, Marte A Becker, Jessica Steenkamer, Manon E Wildenberg, Sybren L Meijer, Christianne J Buskens, Willem A Bemelman, Mark Löwenberg, Cyriel Y Ponsioen, Gijs R van den Brink, Geert R D'Haens   +10 more
doaj   +1 more source

Development and validation of enzyme-linked immunosorbent assays for the measurement of infliximab and anti-drug antibody levels

Heliyon, 2023
Infliximab and its anti-drug antibody (ADA) serum concentrations exhibit a strong correlation with clinical response and loss of response. The use of therapeutic drug monitoring to measure the concentration of infliximab and ADA can facilitate clinical ...
Dong Xiang, Ninghong Li, Lu Liu, Hengyi Yu, Xiping Li, Tinghui Zhao, Dong Liu, Xuepeng Gong   +7 more
doaj   +1 more source

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events

Current Oncology, 2021
Background and aims: Current guidelines state that infliximab is contraindicated for the treatment of immune checkpoint inhibitor-related hepatitis (ir-hepatitis) due to the risk of inducing further liver damage.
Daniel V. Araujo, Thiago Pimentel Muniz, Anjie Yang, Sareh Keshavarzi, Hadas Sorotsky, Marcus O. Butler, Samuel Saibil, Anna Spreafico, David Hogg   +8 more
doaj   +1 more source

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?

Frontiers in Pharmacology, 2020
ObjectiveTo compare the market dynamics of biosimilar infliximab among four Organization for Economic Cooperation and Development (OECD) countries (UK, France, Japan, and Korea) where supply-side and demand-side policies varied greatly, given high and ...
Yujeong Kim, Hye-Young Kwon, Hye-Young Kwon, Brian Godman, Brian Godman, Brian Godman, Evelien Moorkens, Steven Simoens, SeungJin Bae   +8 more
doaj   +1 more source

Infliximab‐induced seizures in a patient with Crohn’s disease: a case report

BMC Gastroenterology, 2021
Background Infliximab-induced seizures in patients with Crohn’s disease are extremely rare and the mechanism of infliximab-induced seizures is unclear.
Zhijie Lv, Xiaoqi Zhang, Li Wu
doaj   +1 more source

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

BMC Musculoskeletal Disorders, 2011
Background This study in patients with rheumatoid arthritis (RA) treated with infliximab describes prospectively the course of (anti)infliximab levels within an infusioncycle to assess at what moment patients develop low/no infliximab trough levels and ...
van Riel Piet LCM, Hekster Yechiel A, Wolbink GJ, den Broeder Alfons A, van den Bemt Bart JF, Benraad Bart, van den Hoogen Frank HJ   +6 more
doaj   +1 more source

Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis.

مجلة كلية الطب, 2015
Background: Rheumatoid arthritis is a common chronic and destructive autoimmune arthropathy .Treatment with infliximab gives great improvement to a large numbers of patients with RA ,however, in some patients after prolonged treatment infliximab can ...
Mohammed A. Al-Karkhi, Muhammed M. Al-Ani, Nizar A. Jassim   +2 more
doaj   +1 more source